Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-56286 in Multiple System Atrophy
NCT06568237Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of emrusolmin in multiple system atrophy (MSA), sponsored by Teva Pharmaceutical Industries Ltd.. Started Oct 2024; status: active, not recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06568237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568237.